Co-Authors
This is a "connection" page, showing publications co-authored by MEENAKSHI ANURAG and GEORGE MILES.
Connection Strength
0.723
-
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. Cell Rep Med. 2025 Jun 17; 6(6):102154.
Score: 0.232
-
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605.
Score: 0.194
-
NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis. Cancer Lett. 2026 Sep 01; 655:218636.
Score: 0.062
-
Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 2025 Nov 03; 15(11):2326-2343.
Score: 0.060
-
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
Score: 0.051
-
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021 03 08; 39(3):361-379.e16.
Score: 0.043
-
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell. 2020 11 25; 183(5):1436-1456.e31.
Score: 0.042
-
Microscaled proteogenomic methods for precision oncology. Nat Commun. 2020 Jan 27; 11(1):532.
Score: 0.040